Expanding Theranostic Strategy Beyond PSMA & SSTR to Unlock Broader Clinical Utility Across Oncology

• Evaluating how next-generation theranostic targets including HER2, B7-H3, FAP and DLL3 may expand precision radiopharmaceutical strategies into broader solid tumour settings
• Determining how diagnostic-therapeutic pairing strategies must evolve across alpha emitters, beta emitters and emerging targeting modalities to maximise translational success
• Understanding the operational, manufacturing and clinicaldevelopment challenges associated with scaling integrated theranostic platforms across global oncology networks

Session reserved for Star Pharma